New drug combo aims to shrink lung tumors before surgery
NCT ID NCT07122687
First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether adding an experimental drug (IBI363) or the approved drug Keytruda to standard chemotherapy can better shrink tumors before surgery in people with stage IB to III non-squamous lung cancer. About 170 participants will be randomly assigned to one of two treatment groups. The main goals are to see how many patients have no cancer left after treatment and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI363 (an experimental immunotherapy) and pembrolizumab (Keytruda, an approved immunotherapy)
- What this could lead to
- If it works, this could point toward a better way to shrink lung tumors before surgery, potentially improving long-term outcomes.
- What could go wrong
- This is a mid-stage trial with only 170 people, so results may not apply to everyone. Side effects from immunotherapy and chemotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE IB-III NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Liaoning Cancer Hospital and Institute
RECRUITINGShenyang, Liaoning, 110000, China